190 related articles for article (PubMed ID: 23679318)
1. Plasma vascular endothelial growth factors A and C in patients undergoing prostatic biopsy and TURP for suspected prostatic neoplasia.
Singh A; Gautam KA; Dalela D; Sankhwar S; Natu S; Sankhwar P; Srivastava A
Asian Pac J Cancer Prev; 2013; 14(3):2053-8. PubMed ID: 23679318
[TBL] [Abstract][Full Text] [Related]
2. Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia.
Voss M; Trojan L; Steidler A; Weiss C; Grobholz R; Alken P; Michel MS
Anal Quant Cytol Histol; 2008 Aug; 30(4):199-202. PubMed ID: 18773737
[TBL] [Abstract][Full Text] [Related]
3. Incidentally Detected Adenocarcinoma Prostate in Transurethral Resection of Prostate Specimens: a Hospital Based Study from India.
Varghese J; Kuruvilla PM; Mehta N; Rathore RS; Babu M; Bansal D; Pillai B; Sam MP; Krishnamorthy H
Asian Pac J Cancer Prev; 2016; 17(4):2255-8. PubMed ID: 27221926
[TBL] [Abstract][Full Text] [Related]
4. Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer.
Fryczkowski M; Bułdak RJ; Hejmo T; Kukla M; Żwirska-Korczala K
Dis Markers; 2018; 2018():3852401. PubMed ID: 30186533
[TBL] [Abstract][Full Text] [Related]
5. [Vascular endothelial growth factor in patients with prostate cancer and benign prostatic hyperplasia].
Trapeznikova MF; Shibaev AN; Kazantseva IA; Mironova OS; Gurevich LE; Morozov AP; Urenkov SB; Kushlinskiĭ NE
Vestn Ross Akad Med Nauk; 2005; (5):14-6. PubMed ID: 15960197
[TBL] [Abstract][Full Text] [Related]
6. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
8. [Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ].
Trapeznikova MF; Shibaeva AN; Ianshin AA; Urenkov SB; Mironova OS; Kazantseva IA; Kushlinskiĭ NE
Urologiia; 2004; (1):17-21. PubMed ID: 15022438
[TBL] [Abstract][Full Text] [Related]
9. Predictive values of vascular endothelial growth factor and microvessel-density levels in initial biopsy for prostate cancer.
Kervancioglu E; Kosan M; Erinanc H; Gonulalan U; Oguzulgen AI; Coskun EZ; Ozkardes H
Kaohsiung J Med Sci; 2016 Feb; 32(2):74-9. PubMed ID: 26944325
[TBL] [Abstract][Full Text] [Related]
10. Is there a PSA cut-off value indicating incidental prostate cancer in patients undergoing surgery for benign prostatic hyperplasia?
Tonyali S; Ceylan C; Aglamis E; Dogan S; Tastemur S; Karaaslan M
Arch Ital Urol Androl; 2021 Mar; 93(1):31-34. PubMed ID: 33754606
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen complexed to alpha(1)-antichymotrypsin in the early detection of prostate cancer.
Martínez M; España F; Royo M; Vera CD; Estellés A; Jiménez-Cruz JF; Medina P; Aznar J
Eur Urol; 2000 Jul; 38(1):85-90. PubMed ID: 10859447
[TBL] [Abstract][Full Text] [Related]
12. Frequency of Unnecessarily Biopsies among Patients with Suspicion of Prostate Cancer in Syrian Men.
Bachour DM; Chahin E; Al-Fahoum S
Asian Pac J Cancer Prev; 2015; 16(14):5967-70. PubMed ID: 26320481
[TBL] [Abstract][Full Text] [Related]
13. Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia.
Markin PA; Brito A; Moskaleva N; Fodor M; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; Lyundup AV; Appolonova SA
Lab Med; 2020 Nov; 51(6):566-573. PubMed ID: 32161964
[TBL] [Abstract][Full Text] [Related]
14. Role of free to total prostate specific antigen ratio in serum in the diagnosis of prostatic enlargement.
Bhuiyan AK; Kibria SA; Subhan SS
Bangladesh Med Res Counc Bull; 2004 Aug; 30(2):51-9. PubMed ID: 15813483
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor (VEGF) and prostate pathology.
Botelho F; Pina F; Silva P; Figueiredo G; Cruz F; Lunet N
Int Braz J Urol; 2010; 36(4):430-7; discussion 438. PubMed ID: 20815949
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of vascular endothelial growth factor in patients undergoing prostate biopsy for suspicion of prostate cancer.
Peyromaure M; Goulvestre C; Fulla Y; Grabar S; Debré B; Dinh-Xuan AT
Urology; 2005 Sep; 66(3):687-91. PubMed ID: 16140116
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer.
Jones A; Fujiyama C; Turner K; Fuggle S; Cranston D; Bicknell R; Harris AL
BJU Int; 2000 Feb; 85(3):276-80. PubMed ID: 10671881
[TBL] [Abstract][Full Text] [Related]
18. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer.
Duque JL; Loughlin KR; Adam RM; Kantoff PW; Zurakowski D; Freeman MR
Urology; 1999 Sep; 54(3):523-7. PubMed ID: 10475365
[TBL] [Abstract][Full Text] [Related]
19. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
[TBL] [Abstract][Full Text] [Related]
20. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
